AVEO Pharmaceuticals Inc (AVEO)

3.07
0.04 1.32
NASDAQ : Health Care
Prev Close 3.03
Open 3.04
Day Low/High 2.95 / 3.08
52 Wk Low/High 0.82 / 2.59
Volume 2.63M
Avg Volume 6.25M
Exchange NASDAQ
Shares Outstanding 118.31M
Market Cap 365.57M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotech Stocks Showing Signs Of Resurgence

MarketNewsUpdates.com News Commentary

AVEO Oncology Announces Positive CHMP Opinion For Tivozanib As A Treatment Of Advanced Renal Cell Carcinoma

AVEO Oncology (NASDAQ:AVEO) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has recommended FOTIVDA™ (tivozanib) for...

AVEO Oncology Announces Pivotal Phase 3 TIVO-3 Study Of Tivozanib In Renal Cell Carcinoma Reaches Enrollment Target

AVEO Oncology (NASDAQ: AVEO) today announced that the Company's pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal...

AVEO Oncology Announces Phase 1/2 TiNivo Trial Of Tivozanib And Opdivo® (nivolumab) In RCC Advances To Phase 2

AVEO Oncology (NASDAQ:AVEO) today announced that its Phase 1/2 AVEO-sponsored TiNivo trial evaluating tivozanib in combination with Bristol-Myers Squibb's anti-PD-1 therapy, Opdivo ® (nivolumab), in subjects with...

AVEO Oncology And Biodesix Announce Results From Two Investigator-Sponsored Phase 1 Studies Of HGF Targeted Antibody Ficlatuzumab At The 2017 ASCO Annual Meeting

AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc., co-development partners, today announced the presentation of results from two investigator-sponsored Phase 1 studies of ficlatuzumab at the 2017 American Society of...

AVEO Oncology Announces Completion Of A CHMP Oral Explanation For Tivozanib As A Treatment Of First-Line Renal Cell Carcinoma

AVEO Oncology (NASDAQ:AVEO) today announced its European licensee for tivozanib, EUSA Pharma, has completed an oral explanation to the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the...

AVEO Announces Appointment Of Matthew Dallas As Chief Financial Officer

AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Matthew Dallas as chief financial officer, effective June 1, 2017.

AVEO Issues Statement Regarding The Passing Of Lead Director Henri A. Termeer

The Board of Directors of AVEO Oncology (NASDAQ:AVEO) today issued the following statement regarding the passing of its Lead Director Henri A.

AVEO Oncology Announces Receipt Of USPTO Notice Of Allowance Related To AV-353

AVEO Oncology (NASDAQ: AVEO) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.

AVEO Reports First Quarter 2017 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2017, and provided a business update.

AVEO Announces Presentations At The 2017 ASCO Annual Meeting

AVEO Oncology (NASDAQ:AVEO) today announced that poster presentations for three clinical studies will be presented at the upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2-6, 2017.

AVEO Announces Submission Of Response To Tivozanib Marketing Authorization Application Day 180 List Of Outstanding Issues

AVEO Oncology (NASDAQ: AVEO) today announced that its European licensee for tivozanib, EUSA Pharma, has submitted responses to the European Medicines Agency (EMA) Day 180 List of Outstanding Issues (LOI) related to the...

AVEO Announces Milestone Payment From CANbridge For AV-203

AVEO Oncology (NASDAQ:AVEO) today announced receipt of a $500,000 milestone payment from CANbridge Life Sciences Ltd.

AVEO Announces Closing Of Public Offering And Full Exercise Of Option To Purchase Additional Shares

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) today announced the closing of its previously announced underwritten public offering of 34,500,000 shares of common stock, including the exercise in full by the underwriter of its...

AVEO Announces Pricing Of $15.0 Million Public Offering Of Common Stock

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has priced an underwritten public offering of 30,000,000 shares of common stock at a price to the public of $0.

AVEO Announces Proposed Offering Of Common Stock

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

AVEO Reports Full Year 2016 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2016 and provided a business update.

AVEO Announces First Patient Dosed In Phase 1/2 TiNivo Trial Of Tivozanib And Opdivo® (nivolumab) In Advanced RCC

AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Phase 1/2 AVEO-sponsored TiNivo trial evaluating tivozanib in combination with Bristol-Myers Squibb's anti-PD-1 therapy, Opdivo®...

AVEO Announces TIVO-3 Passes The First Safety Monitoring Committee Safety Review

AVEO Oncology (NASDAQ:AVEO) today announced that its pivotal, Phase 3 TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell...

AVEO Announces Clinical And Regulatory Updates For Tivozanib

AVEO Oncology (NASDAQ:AVEO) today announced clinical and regulatory updates for its lead drug candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).

AVEO To Present At The 19th Annual BIO CEO & Investor Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle, M.

AVEO Announces Submission Of Responses To The EMA Day 120 List Of Questions For Marketing Authorization Application For Tivozanib In Renal Cell Carcinoma

AVEO Announces Submission Of Responses To The EMA Day 120 List Of Questions For Marketing Authorization Application For Tivozanib In Renal Cell Carcinoma

AVEO Oncology (NASDAQ:AVEO) today announced that its development partner, EUSA Pharma, a specialty pharmaceutical company with a focus on oncology and oncology supportive care, has submitted its responses to the European...

AVEO To Present At The 28th Annual Piper Jaffray Healthcare Conference

AVEO To Present At The 28th Annual Piper Jaffray Healthcare Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 28 th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 3:30 PM Eastern...

AVEO Oncology Reports Third Quarter 2016 Financial Results And Provides Business Update

AVEO Oncology Reports Third Quarter 2016 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2016.

AVEO To Present At The 15th Annual BIO Investor Forum

AVEO To Present At The 15th Annual BIO Investor Forum

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 15th Annual BIO Investor Forum on Wednesday, October 19, 2016 at 11:30 AM Pacific Time.

AVEO Oncology Announces Proposed Settlement And Settlement Hearing In 2014 Stockholder Litigation

AVEO Oncology Announces Proposed Settlement And Settlement Hearing In 2014 Stockholder Litigation

AVEO Oncology (NASDAQ:AVEO) today announced that a settlement hearing will be held on December 19, 2016 at 3:00 p.

AVEO To Present At The 18th Annual Rodman & Renshaw Global Investment Conference

AVEO To Present At The 18th Annual Rodman & Renshaw Global Investment Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 18 th Annual Rodman & Renshaw Global Investment Conference on Monday, September 12, 2016 at...

AVEO Initiates The Evaluation Of Tivozanib In Combination With Bristol-Myers Squibb's Opdivo® (nivolumab) In Advanced Renal Cell Carcinoma

AVEO Initiates The Evaluation Of Tivozanib In Combination With Bristol-Myers Squibb's Opdivo® (nivolumab) In Advanced Renal Cell Carcinoma

AVEO Oncology (NASDAQ:AVEO) today announced the initiation of a clinical evaluation of AVEO's oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), tivozanib, in combination with...